prizloncabtagene autoleucel
A preparation of autologous T lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, prizloncabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
| Synonym: | autologous anti-CD19/anti-CD20 CAR T cells EXP039 autologous anti-CD19/CD20 CAR-T cells C-CAR039 autologous CD19/CD20-targeting CAR T cells EXP039 autologous CD19/CD20-targeting CAR-T cells EXP039 |
|---|---|
| Code name: | C CAR039 C-CAR039 CCAR039 EXP 039 EXP-039 EXP039 |